Sign up for our complimentary
weekly e-journal

Main Newsletter
Mastery Series
Therapy Series
 
Bookmark and Share | Print Article | Items for the Week Previous | All Articles This Week | Next
This article originally posted and appeared in  PreventionPractice MgmtPublic HealthIssue 647

Diabetes Screening May Not Reduce Death Rates

Without the knowledge of what to do once diagnosed, nothing really happens....
Advertisement

Researchers looked at the number of deaths over 10 years among more than 20,000 people, aged 40 to 69. All of them were at high risk for diabetes.

The patients were divided into three groups. One group underwent a round of diabetes screening that was followed up by routine care for those diagnosed with diabetes; another group had a round of screening followed by intensive management for those diagnosed with diabetes; and a third group did not undergo diabetes screening.

Over an average follow-up of nearly 10 years, the overall death rates in the groups that had diabetes screening were no lower than in the group that had no screening. There also was no significant difference between the groups in the number of deaths specifically from diabetes, cardiovascular illness, cancer or other causes.

Study author Dr. Simon Griffin, of the epidemiology unit at Addenbrooke's Hospital in Cambridge, said in a journal news release, "It seems that the benefits of screening might be smaller than expected and restricted to individuals with detectable disease." "However, benefits to the population could be increased by including the detection and management of cardiovascular risk factors alongside the assessment of diabetes risk, performing repeated rounds of screening and improving strategies to maximize the uptake of screening."

Michael Engelgau, of the U.S. Centers for Disease Control and Prevention, wrote in an accompanying editorial, "Diabetes screening and diagnosis can be done with relative ease, which further escalates popular support for wide-scale screening." "However, these compelling arguments overlook the screening costs, potential harm and lack of clear evidence that screening improves health outcomes compared with current routine clinical diagnosis."

"This study increases the doubt about the value of wide-scale screening for undiagnosed diabetes alone, and deserves credit for tackling the screening quandary head-on," Engelgau concluded. "Nevertheless, for any one study to address the diverse factors that affect screening policies -- ranging from the magnitude of population burden of disease to the capacity and effectiveness of prevention approaches -- is a tall order. Screening recommendations are therefore likely to be country specific and context specific for the foreseeable future."

The Lancet, news release, Oct. 3, 2012  

Advertisement


 

Bookmark and Share | Print | Category | Home

This article originally posted 12 October, 2012 and appeared in  PreventionPractice MgmtPublic HealthIssue 647

Past five issues: Issue 779 | SGLT-2 Inhibitors Special Edition April 2015 | Diabetes Clinical Mastery Series Issue 238 | Issue 778 | Diabetes Clinical Mastery Series Issue 237 |

2015 Most Popular Articles:

Glyburide Used for Gestational Diabetes May Increase Risk of Birth Complications
Posted April 02, 2015
A Potential New Type 2 Diabetes Indicator
Posted April 02, 2015
A Third Treatment Option in Uncontrolled Type 2 Diabetes
Posted April 02, 2015
Gastric Electrical Stimulation an Alternative to Insulin Injections?
Posted April 02, 2015
Women Retain Insulin Sensitivity Better than Men
Posted April 02, 2015
A Novel Scale May Indicate Glycemic Progression to Type 1 Diabetes
Posted April 02, 2015
Artificial Pancreas Software Algorithm Receives Approval in Europe
Posted April 02, 2015
FDA Panel Recommends New CV Safety Warnings on Onglyza and Nesina DPP-4s
Posted April 17, 2015
HbA1c and OGTT Performance in Prediabetic Obese Adolescents
Posted April 02, 2015
Glycemic Control and Medications in T2DM Elderly with Dementia
Posted April 02, 2015


Browse by Feature Writer & Article Category.
A. Lee Dellon, MD | Aaron I. Vinik, MD, PhD, FCP, MACP | Beverly Price | Charles W Martin, DD | Derek Lowe, PhD | Dr. Brian Jakes, Jr. | Dr. Fred Pescatore | Dr. Tom Burke, Ph.D | Eric S. Freedland | Evan D. Rosen | Ginger Kanzer-Lewis | Greg Milliger | Kristina Sandstedt | Laura Plunkett | Leonard Lipson, M.A. | Louis H. Philipson | Maria Emanuel Ryan, DDS, PhD | Marilyn Porter, RD, CDE | Melissa Diane Smith | Michael R. Cohen, RPh, MS, ScD, FASHP | Paul Chous, M.A., OD | Philip A. Wood PhD | R. Keith Campbell, Professor, B.Pharm, MBA, CDE | Richard K. Bernstein, MD | Sheri R. Colberg PhD | Sherri Shafer | Stanley Schwartz, MD, FACP, FACE | Steve Pohlit | Steven V. Edelman, M.D. | Timothy S. Hollingshead |

Cast Your Vote
Would you like to see more CE on the newest drugs for diabetes?
CME/CE of the Week
Hugh G. Calkins, MD, and Joseph Edward Marine, MD

Category: Cardiology
Credits:
 1
Search Articles On Diabetes In Control